Abstract
Influenza is an important epidemic and pandemic illness associated with serious morbidity and mortality in unprotected communities. Patients at increased risk of infection are those with pre-existing cardiopulmonary disease including asthma. The influenza virus has the ability to produce antigenic changes posing problems for vaccine development.
Influenza vaccines have been available for over 50 years. Despite the continuing global threat posed by infection and recommendations in many countries that immunisation should be widely given, uptake rates are variable and often poor. It has been demonstrated that infection with influenza and other respiratory viral pathogens can produce exacerbations of asthma throughout the age groups. Despite this, vaccine uptake rates in asthmatic populations are quite low. Poor uptake rates are attributed to a number of factors and we review the evidence for the widely held view that influenza vaccination produces exacerbations of chronic airflow obstruction including asthma. Observational studies have found conflicting results: some post immunisation changes in bronchial hyperreactivity and increased requirements of bronchodilator therapy have been in some, but not all, studies. Placebo-controlled trials have not demonstrated any clinical deterioration although one study showed a small reduction in peak expiratory flow rate. Intranasal administration of cold-adapted live vaccines and new nucleic acid vaccines are briefly considered. Live adapted vaccines have been shown to be effective in influenza immunoprophylaxis and limited data on their use in patients with asthma suggest that they can be administered safely.
In conclusion, based up on current studies and evidence, it seems likely that influenza infection produces morbidity in patients with asthma but that any potential adverse effects of influenza immunisation are outweighed by the benefits in this population. However, placebo-controlled trials are few and only small numbers of asthmatic patients have been investigated.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Meiklejohn G, Eickhoff TC, Graves P, et al. Antigenic drift and efficacy of influenza virus vaccines. J Infect Dis 1978 Nov; 138: 618–24
Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992; 7: 26–37
Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics. Arch Intern Med 1982 Jan; 142: 85–9
Nguyen-Van-Tam JS, Nicholson KG. Influenza deaths in Leicestershire during the 1989–90 epidemic: implications for prevention. Epidemiol Infect 1992; 108: 537–455
Chonmaitree T, Howie VM, Truant AL. Presence of respiratory viruses in middle ear fluids and nasal wash specimens from children with acute otitis media. Pediatrics 1986; 77: 698–702
McIntosh K, Ellis EF, Hoffman LS, et al. The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. Pediatrics 1973; 82: 578–90
Minor TE, Dick EC, DeMeo AN, et al. Viruses as precipitants of asthmatic attacks in children. JAMA 1974 Jan; 227(3): 292–8
Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ 1995 May; 310: 1225–9
Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993 Oct; 307: 982–6
Beasley R, Coleman ED, Hermon Y, et al. Viral respiratory tract infection and exacerbations of asthma in adult patients. Thorax 1988; 43: 679–83
Busse WW. The contribution of viral respiratory infections to the pathogenesis of airway hyperreactivity. Chest 1988 May; 93: 1076–82
Serwint JR, Miller RM, Korsch BM. Influenza type A and B infections in hospitalised pediatric patients. Am J Dis Child 1991 June; 145: 623–6
Housworth J, Langmuir AD. Excess mortality from epidemic influenza 1957–66. Am J Epidemiol 1974; 100: 40–3
Glezen P, Decker M, Perrotta D. Survey of underlying conditions of persons hospitalised with acute respiratory disease during the influenza epidemics in Houston 1978–81. Am Rev Resp Dis 1987; 136: 550–5
Van Voris LP, Newell PM. Antivirals for chemoprophylaxis and treatment of influenza. Semin Respir Infect 1992; 7: 61–70
Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N Engl J Med 1997; 337: 874–80
Sugaya N, Nerome K, Ishida M, et al. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well matched type B. JAMA 1994 Oct; 272: 1122–4
Gross PA, Ennis FA. Influenza vaccine: split product versus whole virus type: how do they differ? N Engl J Med 1977 Mar; 296: 567–8
Potter CW, Oxford JS. Determinants of immunity to infuenza infection in man. Br Med Bull 1979; 35: 69–75
Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952–82. J Infect Dis 1983; 148: 775–84
Monto AS. Influenza vaccine for the elderly. N Engl J Med 1994 Sep; 331: 807–8
Nichol KL. Efficacy effectiveness of inatiated influenza virus vaccine in adults. In: Nicolson KG, Webster RG, Hay AJ, editors. Textbook of infuenza. Oxford: Blackwell, 1998: 358–72
Bell TD, Chai H, Berlow B, et al. Immunisation with killed influenza virus vaccine in children with chronic asthma. Chest 1978 Feb; 73: 140–5
Nicholson KG, Snacken R, Palache AM. Influenza immunisation policies in Europe and the United States. Vaccine 1995; 13: 365–9
Centers for Disease Control. Influenza vaccination levels 1989–1991. JAMA 1992 Nov; 268: 2360
Wiselka MJ, Kent J, Stern M, Nicholson KG. Influenza and asthma. Lancet 1992; 339: 367–8
Hassan WU, Henderson AF, Keaney NP. Influenza vaccination in asthma. Lancet 1992 Jan; 339: 194
Daggett P. Influenza and asthma. Lancet 1992; 339: 367
Ouellette JJ, Reed CE. Increased response of asthmatic subjects to metacholine after influenza vaccine. J Allergy 1965 Nov; 36: 558–63
Kava T, Laitinen LA. Effects of killed and live attenuated influenza vaccine an symptoms and specific airway conductance in asthmatics and healthy subjects. Allergy 1985; 40: 42–7
Kava T. Acute respiratory infection, influenza vaccination and airway reactivity on asthma. Eur J Respir Dis Suppl 1987; 150: 1–38
Ahmed AH, Nicholson KG, Hammersley VS, et al. Influenza vaccination in patients with asthma: effect on peak expiratory flow, asthma symptoms and use of medication. Vaccine 1997 Jun; 15(9): 1008–9
Albazzaz MK, Harvey JE, Grilli EA. Subunit influenza vaccination in adults with asthma: effect on clinical state, airway reactivity and antibody response. BMJ 1987 May; 294: 1196–7
Retailliau HF, Curtis AC, Storr G, et al. Illness after influenza vaccination reported through a nationwide surveillance system 1976–77. Am J Epidemiol 1980; 111(3): 270–8
Park LC, Frank AL, Sullivan M, et al. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996 Aug; 98(2): 196–200
Nicholson KG, Nguyen-Van-Tamme JS, Ahmed AH, et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet 1998 Jan; 351: 326–32
Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly: a randomised placebo controlled trial. JAMA 1990 Sep; 264: 1139–41
Stenius-Aarniala B, Huttunen JK, Pyhala R. Lack of clinical exacerbations in adults with chronic asthma after immunisation with killed influenza vaccine. Chest 1986 Jun; 89: 786–9
Govaert ThME, Dinant GJ, Aretz K. Adverse reactions to influenza vaccine in elderly people: a randomised double blind trial placebo controlled trial. BMJ 1993; 307: 988–90
Campbell BG, Edward RL. Safety of influenza vaccination in adults with asthma. Med J Aust 1984 Jun; 140: 773–8
Johnson PR, Feldman S, Thompson JM, et al. Immunity to influenza A virus in young children: a comparison of natural infection, live and cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986 Jul; 154: 121–7
Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold adapted influenza A virus over inactivated vaccine for A/Washington/80(H3N2) wildtype virus. Lancet 1984 Mar; I: 705–8
Belshe RB, Van Voris LP, Bartram J, et al. Live attenuated influenza A virus vaccine in children: results of a field trial. J Infect Dis 1984 Dec; 150: 834–40
Edwards KM, Dupont WD, Westrich MK, et al. A randomised controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994 Jan; 169: 68–76
Belshe RB, Van Voris LP. Cold recombinant influenza/A/California/10/78(H1N1) virus vaccine in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis 1984 May; 149: 735–9
Belshe RB, Mendelman PM, Treanor JJ, et al. The efficacy of live attenuated cold adapted trivalent intranasal influenza virus vaccine in children. N Engl J Med 1998 May; 338: 1405–12
Feldman S, Wright PF, Webster RG, et al. Use of influenza A virus vaccines in seronegative children: live cold adapted versus inactivated whole virus. J Infect Dis 1985 Dec; 152: 1212–9
Edwards KM, King JC, Steinhoff MC, et al. Safety and immunogenicity of live attenuated cold adapted influenza B/Ann Arbor/1/86 reassortaient virus vaccine in infants and children. J Infect Dis 1991 Apr; 163: 740–5
Laitinen LA, Elkin RB, Empey DW, et al. Bronchial hyperresponsiveness in normal subjects during attenuated influenza virus infection. Am Rev Respir Dis 1991; 143: 358–61
Zeck R, Solliday N, Kehoe T, et al. Respiratory effects of live influenza virus vaccine on healthy older subjects and patients with chronic respiratory disease. Am Rev Respir Dis 1976; 114: 1061–7
MRC Advisory Group on Pulmonary Function Tests in Relation to Live Influenza Vaccines. Trials of live attenuated influenza virus vaccine in patients with chronic obstructive airways disease. Br J Chest Disease 1984; 78: 236–47
Winson LG, Smit JM, Potter CW, et al. Studies with live attenuated influenza virus in chronic bronchitis. Thorax 1977; 32: 726–8
Robinson HL. Nucleic acid vaccines: an overview. Vaccine 1997; 15: 785–7
Ban EM, van Ginkel KW, Simecka JW, et al. Mucosal immunisation with DNA encoding influenza haemagglutinin. Vaccine 1997; 15: 811–4
Barnett ED. Influenza immunisation for children [editorial]. N Engl J Med 1998 May; 338: 1459–61
Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994 Oct; 331: 778–84
Patriarca PA, Strikas RA. Influenza vaccine for healthy adults? N Engl J Med 1995 Oct; 333: 933–4
Nichol KL, Lind A, Margolis KL. The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med 1995 Oct; 333: 889–900
Calman K, Moores Y. Influenza immunisation: extension of current policies to include those over 75 years and over. 1998 Aug. UK Department of Health CMO letter. Report no.: PL/CMO/98/4
Committee on issues and priorities for new vaccine development. Prospects for immunising against influenza A and B. In: New vaccine development; establishing priorities. Washington, DC: National Academy Press, 1992: 342–64
Wilson R. Influenza vaccination. Thorax 1994; 49: 1079–80
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stephenson, I., Nicholson, K.G. Influenza Vaccination and Asthma. BioDrugs 11, 223–228 (1999). https://doi.org/10.2165/00063030-199911040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199911040-00001